Clinical Trials Logo

Filter by:
NCT ID: NCT06245980 Recruiting - Diabetes Mellitus Clinical Trials

Role of SGLT2I in Patients With Myocardial Infarction

Start date: January 1, 2018
Phase:
Study type: Observational

Role of sglt2I in diabetic patients with myocardial infarction

NCT ID: NCT06245941 Recruiting - Myelofibrosis Clinical Trials

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Start date: May 13, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.

NCT ID: NCT06245759 Recruiting - Bladder Cancer Clinical Trials

The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients

Start date: August 31, 2023
Phase:
Study type: Observational

Based on large sample size studies at home and abroad, the prognosis of patients with non-muscular invasive bladder cancer in different sites undergoing transurethral bladder tumor resection was determined, providing important guidance for subsequent clinical treatment and surgical instrument development.

NCT ID: NCT06245707 Recruiting - Clinical trials for Mild Cognitive Impairment

the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This study intends to apply prospective, open, single-center, randomized controlled study to evaluate the cognitive status of patients with Idiopathic membranous nephropathy and the influence of different treatment schemes on the cognitive status of patients with Idiopathic membranous nephropathy, and explore the possible pathophysiological mechanism by using brain magnetic resonance imaging technology.

NCT ID: NCT06245330 Recruiting - Pancreatic Cancer Clinical Trials

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

Start date: July 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

NCT ID: NCT06245122 Recruiting - Advanced Tumors Clinical Trials

A Study of CS23546 in Subjects With Advanced Tumors

Start date: March 27, 2024
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.

NCT ID: NCT06244628 Recruiting - cGVHD Clinical Trials

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

This is a randomized, single-center phase 3 clinical trial without blinding. Iguratimod, as a rheumatoid arthritis medication, is used to treat autoimmune diseases such as Sjögren's syndrome. It has acceptable side effects, good clinical availability, and is cost-effective. The investigators plan to recruit participants for a clinical trial to evaluate the efficacy and safety of Iguratimod in the treatment of chronic GVHD.

NCT ID: NCT06244368 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Start date: January 17, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

NCT ID: NCT06244277 Recruiting - Sleep Disorder Clinical Trials

Chinese Medicine Treatment of Adolescent Sleep Disorders and Sleeping Pills Withdrawal

Start date: December 22, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of traditional Chinese medicine in the treatment of adolescent sleep disorders and the effect of sleeping pills withdrawal.

NCT ID: NCT06244225 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy